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Abstract
Background Uncemented orthopaedic implants rely on
the bone-implant interface to provide stability, therefore it
is essential that a coating does not interfere with the bone-
forming processes occurring at the implant interface. In
addition, local application of high concentrations of
antibiotics for prophylaxis or treatment of infection may be
toxic for osteoblasts and could impair bone growth.
Questions/Purposes In this animal study, we investi-
gated the effect of a commercially available hydrogel,
either unloaded or loaded with 2% vancomycin. We asked,
does unloaded hydrogel or hydrogel with vancomycin (1)
interfere with bone apposition and timing of bone deposi-
tion near the implant surface; and (2) induce a local or
systemic inflammatory reaction as determined by inflam-
mation around the implant and hematologic parameters.
Methods In 18 New Zealand White rabbits, an uncoated
titanium rod (n = 6), a rod coated with unloaded hydrogel
(n = 6), or a rod coated with 2% vancomycin-loaded
hydrogel (n = 6) was implanted in the intramedullary canal
of the left tibia. After 28 days, the bone volume fraction
near the implant was measured with microCT analysis,
inflammation was semiquantitatively scored on histologic
sections, and timing of bone apposition was followed by
semiquantitative scoring of fluorochrome incorporation on
histologic sections. Two observers, blinded to the treat-
ment, scored the sections and reconciled their scores if
there was a disagreement. The hematologic inflammatory
reaction was analyzed by measuring total and differential
leukocyte counts and erythrocyte sedimentation rates in
blood. With group sizes of six animals per group, we had
79% power to detect a difference of 25% in histologic
scoring for infection and inflammation.
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Results No differences were found in the amount of bone
apposition near the implant in the No Gel group (48.65% ±
14.95%) compared with the Gel group (59.97% ± 5.02%;
mean difference [MD], 11.32%; 95% CI, 3.89% to
26.53%; p = 0.16) or for the Van2 group (56.12%± 10.06%;
MD, 7.46; 95% CI, 7.75 to 22.67; p = 0.40), with the
numbers available. In addition, the scores for timing of bone
apposition did not differ between the No Gel group (0.50 ±
0.55) compared with the Gel group (0.33 ± 0.52; MD,
0.17; 95% CI, 0.86 to 0.53; p = 0.78) or the Van2 group
(0.83 ± 0.41; MD, 0.33; 95% CI, 0.36 to 1.03; p = 0.42).
Furthermore, we detected no differences in the histopathol-
ogy scores for inflammation in the No Gel group (2.33 ±
1.67) compared with the Gel group (3.17± 1.59; MD, 0.83;
95%CI,0.59 to 2.26; p = 0.31) or to the Van2 group (2.5±
1.24;MD, 0.17; 95%CI,1.26 to 1.59; p = 0.95). Moreover,
no differences in total leukocyte count, erythrocyte sedi-
mentation rate, and neutrophil, monocyte, eosinophil,
basophil, and lymphocyte counts were present between the
NoGel orVan2 groups comparedwith theGel control group,
with the numbers available.
Conclusion The hydrogel coated on titanium implants,
unloaded or loaded with 2% vancomycin, had no effect on
the volume or timing of bone apposition near the implant,
and did not induce an inflammatory reaction in vivo, with
the numbers available.
Clinical relevance Antibiotic-loaded hydrogel may prove
to be a valuable option to protect orthopaedic implants
from bacterial colonization. Future clinical safety studies
will need to provide more evidence that this product does
not impair bone formation near the implant and prove the
safety of this product.
Introduction
Numerous approaches for locally applying antibacterial
agents are being considered to try to minimize the risk of
implant-related infection in the clinic. For example, bone
cement in patients receiving cemented THA or TKA often
is loaded with antibiotics [21]. Furthermore, a tibia nail
coated with gentamicin-loaded polymer poly(D,L-lactide)
for surgical treatment in closed or open tibial fractures, and
in revisions, was associated with good clinical, laboratory,
and radiologic outcomes after 6 months of followup in
patients [6]. However, cementless THA or TKA currently
lack options for local application of antibiotics. As it is
important to minimize the risk of infection, there is a need
to research alternative strategies to decrease the risk of
infection for uncemented implants.
Ideally, a method for local prophylaxis of cementless
implants should be biocompatible and should not interfere
with bone apposition. One highly promising method for
local prophylaxis of uncemented implants is using a
resorbable, biocompatible hydrogel as a carrier for agents
of interest [17]. Hydrogels generally offer easy application,
flexibility in choice of antimicrobial agents, and complete
resorption of the hydrogel [8, 11, 13, 19].
In previous studies, the commercially available hydrogel
DAC1 (Defensive Antibacterial Coating; Novagenit Srl,
Mezzolombardo, Italy) was shown to exert an antibacterial
effect when loaded with antibiotics in vitro and in vivo
[3, 7]. Various compounds, for example, vancomycin,
gentamicin, or N-acetylcysteine, can be released from this
hydrogel within 96 hours, with a release peak during the
first 2 hours in vitro [3]. Further, the hydrogel loaded with
2% or 5% vancomycin was shown to be effective in
reducing the local bacterial load in a rabbit implant-related
infection model [7]. The hydrogel has been shown to be
capable of resisting removal during implant insertion when
used as a press-fit implant coating on uncemented femoral
stems [3].
A local coating on uncemented implants should not
interfere with the bone apposition near the implant surface,
as this is an important feature for mechanical stability. In
addition, local application of high concentrations of
antibiotics may be toxic for osteoblasts and could impair
bone growth [2, 4]. In previous work, histomorphometric
evaluations showed no differences between the hyaluronic
acid-based hydrogel coating and HYALGAN1 hydrogel
(Fidia Farmaceulici s.p.a, Abano Terme, Italy) on cortical
bone thickness, 12 weeks after application in a rabbit femur
[7]. In the current study, we wished to investigate the effect
of the hydrogel, either unloaded or loaded with 2% van-
comycin, on bone apposition and timing of bone deposition
near the implant surface and the effect on inflammatory
parameters in a rabbit model.
Therefore, in the current rabbit implant-model study, we
asked whether a hyaluronic acid-based hydrogel coating,
either empty or loaded with 2% (v/w) vancomycin: (1)
interferes with bone apposition and timing of bone depo-
sition near the implant surface; and (2) induces a local or
systemic inflammatory reaction as determined by inflam-
mation around the implant and hematologic parameters.
Materials and Methods
Experimental Design
An animal study with 18 rabbits was performed to evaluate
the effect of implant coating on osseointegration and
hematologic parameters. For this purpose an established
in vivo implant-model was used [24]. Briefly, all animals
received a titanium implant unilaterally in the left tibial
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intramedullary canal (Fig. 1). Fluorochromes were
administered at Days 3, 7, and 21 to analyze the timing of
bone formation. After 28 days, the animals were eutha-
nized and explantation of the tibia and rod was done for
microCT and histopathologic analyses. Blood was drawn
preoperatively and weekly after implantation for hemato-
logic analyses. Three groups (n = 6) were included: the
hydrogel alone or loaded with 2% vancomycin, coated on
the implant, were compared with an uncoated implant. The
antibiotic vancomycin was chosen because it is effective
against Gram-positive bacteria such as Staphylococci and
Streptococci [10, 12], which account for more than 2
.
3 of
prosthesis-related infections [20], and is a frequently used
antibiotic in bone cement for local infection prophylaxis
[21].
Animals, Welfare, and Housing
The study was conducted with permission from the local
ethics committee for animal experimentation in Utrecht, the
Netherlands. Female New Zealand White (NZW; Charles
River, L’Arbresle, France) rabbits were ordered at an age of
16 weeks and were allowed to acclimate for 12 to 14 days
before surgery. The rabbits were housed in pairs, except for 2
to 3 days postoperatively until the surgical wounds were
properly closed. Water was available ad libitum and the
rabbits received 100 g of food (Stanrab; SDS, Essex, Eng-
land) daily. The humane endpoint was defined as when the
rabbits would lose weight exceeding 15% in 2 days or when
they would experience shock or sepsis.
Implants and Hydrogel Coating
The average surface roughness of the sandblasted titanium
rods (Adler Ortho srl, Milan, Italy) (diameter 4 mm; length,
25 mm) was 5.6 lm. The surface roughness of the rods was
comparable to that of uncemented femoral stems used for
clinical purposes (Recta; AdlerOrtho srl). DAC1, a patented
hydrogel (Novagenit1) was used as a local carrier for van-
comycin on the implant. Before implantation, the implants
were not coated (No Gel group), coated with hydrogel (Gel
group), or with hydrogel loaded with 2% (w/v) vancomycin
(vancomycin hydrochloride; Hospira Benelux BVBA,
Brussels, Belgium) (Van2 group). The hydrogel was pro-
vided as a sterile powder (60 mg) in a syringe and was
reconstituted during surgery by mixing the powder with 1
mL sterile demineralized water, resulting in a solution with a
concentration of 6% (w/v) hydrogel. In the Van2 group, the
vancomycin was dissolved in the water before mixing with
the hydrogel powder. The hydrogel was applied periopera-
tively on the surface of the titanium rods, using a spreader
attached to the syringe with the hydrogel. The hydrogel was
spread evenly on the complete surface of the titanium rod,
after which the rod was immediately implanted.
Surgery, Analgesia, and Anesthesia
Surgery was performed under aseptic conditions. Preoper-
atively, the animals received subcutaneous buprenorphine
hydrochloride (0.03 mg/kg, Temgesic1; RB Pharmaceuti-
cals Limited, Slough, United Kingdom) for analgesia.
Anesthesia was initiated by subcutaneous injections of
ketamine (10–15 mg/kg; Narketan1 10; Ve´toquinol BV,
‘s-Hertogenbosch, the Netherlands) and Dexdomitor1
(0.15–0.25 mg/kg; Orion Corporation, Espoo, Finland).
Anesthesia was maintained by an intravenous line of 1:10
Dexdomitor1 and ketamine in NaCl.
Before the first incision, the hair of the left hind leg was
removed and the skin was disinfected with 10% povidone-
iodine (Betadine1 solution; Meda Pharma BB, Amstelveen,
the Netherlands). The knee was opened with a medial para-
patellar incision. Anterior to the cruciate ligaments, the tibial
Fig. 1 All animals received a titanium rod (diameter 4 mm; length 25
mm) in the intramedullary canal of the left tibia. Shown here is an AP
radiograph of the knee obtained immediately after implantation of the
implant.
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intramedullary canal was opened with an awl and reamed
with a drill (diameter, 4.1 mm). Next, the implant, with or
without hydrogel was implanted. The joint and skin were
closed with Vicryl1 size 3-0 (Ethicon Inc, Johnson & John-
son, Peterborough,Ontario, Canada) andMonocryl1 size 3-0
(Ethicon), respectively. Radiographs were taken to verify the
position of the implants in the proximal intramedullary tibial
cavity and to verify an undamaged cortex. Anesthesia was
reversed with AtipamTM (0.5–1.0 mg/kg; Eurovet Animal
Health BV, Bladel, the Netherlands). Postoperative analgesia
with buprenorphine hydrochloride (0.03 mg/kg, subcuta-
neous) was administered every 8 hours for 48 hours.
Fluorochrome Administration
Fluorochrome labels can be incorporated at sites of min-
eralization of bone and labels the front of mineralization at
the time of administration [22]. By administering the labels
at different times, bone formation can be followed with
time. To observe bone apposition in the current study,
rabbits were injected with two fluorochrome labels: xylenol
orange (Xylenol Orange tetrasodium salt, 398187; Sigma-
Aldrich, St Louis, MO, USA) and calcein green (Calcein
disodium salt, 21030; Sigma-Aldrich). Two different
administration schedules were used for analysis of early
and late fluorochrome deposition. In each group, half of the
animals were injected on Days 3 and 10 and the other half
were injected on Days 7 and 21 with xylenol orange and
calcein green respectively.
Postoperative Followup and Euthanasia
Blood was collected preoperatively and weekly thereafter
for analyses of total and differential leukocyte counts
(neutrophils, monocytes, eosinophils, basophils, and lym-
phocytes), and erythrocyte sedimentation rates (ESRs). The
analyses were performed by the Department of Clinical
Chemistry and Haematology (UMC Utrecht, The Nether-
lands). The animals were euthanized 28 days after surgery
with an overdose of intravenous sodium pentobarbital
(Euthanimal1 40%; Alfasan Nederland BV, Woerden, the
Netherlands), after inducing general anesthesia. This time
was chosen to be able to detect differences between the
groups during an early phase of bone formation.
Postmortem Sample Acquisition and Analyses
The operative areas were depilated and disinfected with
10% povidone-iodine. The proximal tibiae were explanted
under sterile conditions with a saw (Dremel1 Model 300;
Dremel Europe, Breda, the Netherlands) and placed in 10%
formalin.
For microCT imaging for bone volume fraction analysis,
all samples (six per group) were scanned after fixation with
formalin using a microCT scanner (Quantum FX MicroCT;
Perkin Elmer, Waltham, MA, USA) with a voxel size of 60
9 60 9 60 lm3. The images were reconstructed automat-
ically in three dimensions using the built-in microCT
software (Analyze 11.0). Bone apposition near the implant
was measured as the percentage of bone volume within a
distance of 180 lm from the entire cylindrical surface
(excluding the ends) of the implant.
For histopathology and fluorochrome analyses, the tibia
containing the implant was embedded after performing
microCT. After fixation, the samples were dehydrated
through a graded ethanol series and embedded in
methylmethacrylate. Per mL, the methylmethacrylate
solution consisted of 0.8 mL methylmethacrylate (Merck
KGaA, Darmstadt, Germany), 0.2 mL Plastoid1-N
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany),
and 28 mg benzoyl peroxide (Sigma-Aldrich, St Louis,
MO, USA). After methylmethacrylate polymerization,
sections of 20 to 30 lm were cut on a microtome (Leica
SP1600; Leica Biosystems Nussloch GmbH, Nussloch,
Germany). Per animal, two sections (one distal and one
proximal section) of the left tibia with the rod were made
for histopathology and two sections were made for fluo-
rochrome analysis.
For histopathology, the sections were stained with 1%
methylene blue solution and subsequently with 0.3% basic
fuchsin solution. For semiquantitative scoring of inflam-
mation, the scoring system by Vogely et al. [24] was used.
This system quantifies 11 inflammation parameters which
results in a score between 0 (no reaction) and 56 (serious
reaction). Per animal, two sections (one distal and one
proximal section) were scored. Two observers (WB and
PGJN), blinded to the treatment, scored the sections and
reconciled their scores if there was disagreement.
To examine the timing of bone apposition on the
implant surface, unstained sections were analyzed micro-
scopically for the presence of fluorochromes adjacent to the
implant. If a particular fluorochrome was present a score of
1 was given, if there was no bone or fluorochrome present
around the implant, a score of 0 was given. Scoring was
performed by two observers blinded to the treatment (WB
and MHPvR), and they reconciled their scores if there was
disagreement. Scores were averaged per group. As two
different schedules were used for administering fluo-
rochromes, three animals were included for each time. One
proximal and one distal section were scored per animal.
Results were incomplete as one rabbit from the No Gel
group was not injected with xylenol orange on Day 3.
Furthermore, calcein green was not administered to six of
Boot et al. Clinical Orthopaedics and Related Research1
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nine rabbits on Day 10, therefore the results of these ani-
mals were excluded from further analysis.
Statistical Analyses
With the group sizes used in our study, we had 79% power
to detect a difference of 25% in histologic scoring for
infection and inflammation at a probability less than 0.05
[24]. This outcome parameter was used for the power
calculation as no existing data for bone-volume fraction for
this specific animal model were available. The results from
the microCT, histopathologic analyses, and the blood val-
ues for each time were compared by a one-way ANOVA
with Dunnett’s post hoc test, including the No Gel group as
the control. All statistical calculations were performed
using SPSS Version 20.0 (IBM Corp, Armonk, NY, USA).
A probability value less than 0.05 was considered signifi-
cant and results are presented as mean (± SD), mean
difference (MD), and 95% CI.
Results
Bone Apposition and Timing of Bone Deposition Near
the Implant Surface
Bone Apposition
All three groups showed bone volume fraction percentages
near the implant surface between 49% and 60% (Fig. 2A).
The bone volume fraction percentage in the No Gel group
was 48.65% ± 14.95% (Fig. 2B). With the numbers
available, no differences were found in bone volume
fraction percentages for the Gel group (59.97% ± 5.02%;
MD, 11.32%; 95% CI, 3.89% to 26.53%; p = 0.16) or for
the Van2 group (56.12% ± 10.06%; MD, 7.46%; 95% CI,
7.75% to 22.67%; p = 0.40) compared with the No Gel
group.
Histologic Analysis of Fluorochrome Incorporation for
Timing of Bone Deposition
All animals showed similar fluorochrome incorporation
patterns. Most animals showed mild periosteal bone for-
mation, in some cases already by Day 3 (Fig. 3A). None of
Fig. 2A–B The bone volume fraction percentages near the implant
surface were measured for all groups using microCT. (A) The bone
present within 180 lm from the implant surface is shown in blue-
green. (B) No differences were found in the bone volume percentages
near the implant of the Gel or Van2 groups compared with the No Gel
group. Data are shown as mean and SD.
Fig. 3A–B Fluorochrome incorporation was analyzed microscopi-
cally, and bright-field and fluorescence pictures were taken from the
same areas. The microscopic view of the fluorochrome signals was
projected on the corresponding bright-field picture. Shown are
representative examples of slides from an animal (Van2 group)
injected with fluorochromes on (A) Days 3 and 10 and (B) Days 7 and
21. All animals showed similar fluorochrome incorporation in newly
formed bone in the cortex (pink arrows), around the implant (blue
triangles), and in periosteal bone (yellow star). In Illustration B, the
dark circle is an air bubble that got incorporated during the
embedding process.
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the rabbits showed fluorochrome apposition around the
implant on Day 3 (Table 1). No differences were found in
averaged scores for active bone formation on Day 7 for the
Gel group (0.33 ± 0.52) compared with the No Gel group
(0.50 ± 0.55; MD, 0.17 95% CI, 0.86 to 0.53; p =
0.78), nor for the Van2 group compared with the No Gel
group (0.83 ± 0.41; MD, 0.33; 95% CI, 0.36 to 1.03; p =
0.42), with the numbers available. On Day 21, bone growth
around the implant was present in all animals (Table 1;
Fig. 3B).
Local and Systemic Inflammation
Histopathology
Microscopic analysis of the histologic slides showed few
signs of inflammation. The scores in the No Gel group
(2.33 ± 1.67) did not differ, with the numbers available,
from those of the Gel control group (3.17 ± 1.59; MD,
0.83; 95% CI, 0.59 to 2.26; p = 0.31), nor did the Van2
group (2.5 ± 1.24; MD, 0.17; 95% CI, 1.26 to 1.59; p =
0.95) (Fig. 4A). In general, the Haversian canals were
slightly enlarged and there was a mild periosteal reaction
observed in all groups (Fig. 4B–C). The similarities in
histologic appearance of the groups was confirmed by the
histopathology scores for inflammation that ranged from 0
to 56, with 0 representing no inflammation and 56 repre-
senting severe inflammation.
Hematology
The hydrogel coating did not result in a hematologic
reaction based on the parameters we measured (Fig. 5). No
differences in total leukocyte count, ESR, and neutrophil,
monocyte, eosinophil, basophil, and lymphocyte counts
were present between the No Gel or Van2 groups com-
pared with the Gel control group, with the numbers
available. The only exception was the leukocyte count
between the No Gel (7.52 ± 1.81 9 109/L) and Gel groups
on Day 28 ((4.70 ± 1.21 9 109/L; MD, 2.48; 95% CI,
4.80 to 0.17; p = 0.04)).
Table 1. Timing of bone growth around the implant
Group Day 3 Day 7 Day 21
No Gel 0 ± 0 0.5 ± 0.5 1 ± 0
Gel 0 ± 0 0.3 ± 0.5 1 ± 0
Van2 0 ± 0 0.8 ± 0.4 1 ± 0
Data are shown as mean ± SD; Van2 = hydrogel loaded with 2%
vancomycin; the presence of a fluorochrome on a certain time would
result in a score of 1, the absence in a score of 0. For each time, 6
sections were evaluated, except for the No Gel group on Day 3 where
4 sections were evaluated.
Fig. 4A–C (A) Semiquantitative scoring for inflammation parame-
ters was performed on the basic fuchsin and methylene blue stained
sections. The data are presented in boxplots with median and range.
The circle and stars indicate an outlier and far outliers, respectively.
(B) A representative microscopic image of a histologic slide is shown
together with (C) a higher magnification image. All samples showed
bone apposition (pink) on the surface of the implant (black). In most
animals some Haversian canals were slightly enlarged (green arrows),
and a mild periosteal reaction (yellow star) could be observed.
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Discussion
Currently, numerous approaches for locally applying
antibacterial agents are being researched for prophylaxis of
infection for uncemented implants [5, 14, 17, 18]. As bone
apposition at the implant surface allows for increased sta-
bility of these implants, local antibiotic coatings should not
interfere with this process. Therefore, we asked: does a
hydrogel or hydrogel loaded with vancomycin (1) interfere
with bone apposition and timing of bone deposition near
the implant surface; and (2) induce a local or systemic
inflammatory reaction as determined by inflammation
around the implant and hematologic parameters? In this
study, we showed that the tested hydrogel, either unloaded
or loaded with 2% vancomycin, did not interfere with bone
apposition and timing of bone deposition near the implant
surface, and did not induce inflammation around the
implant or a systemic inflammatory reaction in a rabbit
tibial intramedullary rod model. Only slight changes in
morphologic features of the bone were observed, including
a mild periosteal reaction and minimally enlarged Haver-
sian canals. These changes might be a reaction to the
presence of the implant as these were observed in all
groups.
This study had several limitations. First, this was a rel-
atively small animal study, especially for proving the
Fig. 5A–G Blood values were
measured preoperatively, and
weekly during the study. Total
(A) leukocyte, (B) neutrophil,
(C) eosinophil, (D) lymphocyte,
(E) basophil, and (F) monocyte
counts, and the (G) erythrocyte
sedimentation rate (ESR) for all
three groups are shown. Data
are shown as mean and SD. *p
\ 0.05 compared with the No
Gel control group, at each time.
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absence of an effect of the hydrogel on bone growth. In
previous work with this product, histomorphometric eval-
uations showed no differences in cortical bone thickness
between the hyaluronic acid-based hydrogel and HYAL-
GAN1 hydrogel application in a rabbit femur [7].
However, to show the clinical safety of using a hydrogel as
a local carrier of antibiotics for orthopaedic implants, this
product will need to be validated in a more robust way, for
example, a clinical safety study. Second, 28 days followup
seems a rather early time to evaluate bone formation.
However, at a later time most bone apposition near the
implant surface might be near completion which eliminates
the possibility of finding differences. In all cases, bone
formation around the implant was observed at Day 21, as
has been shown by the fluorochrome labels. Therefore, we
chose Day 28 as the end-point of the study. Third, the
implant model used in this study does not involve a press-
fit situation for the implant. Therefore, no conclusions can
be drawn regarding stability of the implant.
High local concentrations of antibiotics may be toxic for
osteoblasts and could impair bone growth [2, 4]. This would
be an unwanted side effect for a local carrier for use in
uncemented orthopaedic implants, as optimal bone deposi-
tion around the implant is needed for implant stability. In all
animals, comparable bone apposition near the implant was
observed. At Day 28, the empty hydrogel (59.97%) and the
2% vancomycin-loaded hydrogel (56.12%) showed similar
levels of bone volume fraction percentages as the group with
uncoated implants (48.65%). Furthermore, all animals
showed active bone formation around the implant byDay 21.
These results suggest that, in this animal model, the hydro-
gel, either empty or loaded with 2% vancomycin, does not
impair bone formation and that 2% vancomycin was an
acceptable concentration to be applied locally.
Inflammation may compromise bone development and
delay bone remodeling [1, 9]. None of the animals showed
severe signs of inflammation according to the results of the
grading system of Vogely et al. [24]. Only slight changes in
morphologic features of the bone were observed, including
a mild periosteal reaction and minimally enlarged Haver-
sian canals. These changes might be a reaction to the
presence of the implant as these were observed in all
groups. In addition, there were no meaningful differences
in blood values during the study period. These findings
suggest that the hydrogel does not induce an inflammation.
One of the potential benefits of using a hydrogel for
local delivery of agents is the flexibility in the choice of the
functional agent, which possibly can provide personalized
antibacterial prophylaxis. Especially for uncemented
implants, it would be interesting to explore the possibilities
of adding osteoinductive or osteoconductive components
next to the antibacterial agents to further improve the bone-
implant interface of uncemented implants. A combination
of the bone-inducing molecule recombinant human BMP-2
and the antibiotic teicoplanin loaded in the synthetic,
degradable polymer poly(D,L-lactic acid)-p-dioxanone-
polyethylene glycol resulted in controlled release of tei-
coplanin for up to 14 days, and critical-sized parietal
cranial bone defects in rats were consistently filled with
new-formed bone after implantation [16].
An interesting property of hydrogels is that they can be
adapted to create a material with specific characteristics
that might improve the functionality, for example ther-
moreversibility, which means that the gels are liquid at
lower temperatures and gelate at higher temperatures. In
this manner, the hydrogel could be easily syringeable,
which allows for easy application, and after gelation the
loaded antibiotics could be released in a controlled manner
[15, 23]. The versatility of hydrogels and the possibilities
to adapt a hydrogel with specific characteristics makes it an
interesting candidate for use as a local carrier for agents of
interest. Future research could provide more knowledge
regarding the ideal properties of a local hydrogel coating
for infection prophylaxis and the choice of agents to be
loaded in a hydrogel.
In the current animal study, we found that DAC1
hydrogel could be applied as a coating on titanium implants
without impairing bone formation near the implant surface
or inducing an inflammatory reaction. Future clinical safety
studies may provide additional evidence that this hydrogel
does not hinder bone formation and prove the safety of this
product. Antibiotic-loaded hydrogel may be a valuable
option to offer local protection of orthopaedic implants
from bacterial colonization.
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